Literature DB >> 19937977

Association study of NRG1, DTNBP1, RGS4, G72/G30, and PIP5K2A with schizophrenia and symptom severity in a Hungarian sample.

János M Réthelyi1, Steven C Bakker, Patrícia Polgár, Pál Czobor, Eric Strengman, Péter I Pásztor, René S Kahn, István Bitter.   

Abstract

Genetic association studies have yielded extensive but frequently inconclusive data about genetic risk factors for schizophrenia. Clinical and genetic heterogeneity are possible factors explaining the inconsistent findings. The objective of this study was to test the association of commonly incriminated candidate genes with two clinically divergent subgroups, non-deficit (SZ-ND) and deficit-schizophrenia (SZ-D), and symptom severity, in order to test for replication of previously reported results. A homogeneous sample of 280 schizophrenia patients and 230 healthy controls of Hungarian, Caucasian descent were genotyped for polymorphisms in schizophrenia candidate genes NRG1, DTNBP1, RGS4, G72/G30, and PIP5K2A. Patients were divided into the diagnostic subgroups of SZ-ND and SZ-D using the Schedule for Deficit Syndrome (SDS), and assessed clinically by the Positive and Negative Symptom Scale (PANSS). SNP8NRG241930 in NRG1 and rs1011313 in DTNBP1 were associated with SZ-ND (P = 0.04 and 0.03, respectively). Polymorphisms in RGS4, G72/G30, and PIP5K2A were neither associated with SZ-ND nor with SZ-D. SNP8NRG241930 showed association with the PANSS cognitive and hostility/excitability factors, rs1011313 with the negative factor and SDS total score, and rs10917670 in RGS4 was associated with the depression factor. Although these results replicate earlier findings about the genetic background of SZ-ND and SZ-D only partially, our data seem to confirm previously reported association of NRG1 with schizophrenia without prominent negative symptoms. It was possible to detect associations of small-to-medium effect size between the investigated candidate genes and symptom severity. Such studies have the potential to unravel the possible connection between genetic and clinical heterogeneity in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19937977     DOI: 10.1002/ajmg.b.31049

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  26 in total

1.  Nucleocytoplasmic shuttling of dysbindin-1, a schizophrenia-related protein, regulates synapsin I expression.

Authors:  Erkang Fei; Xiaochuan Ma; Cuiqing Zhu; Ting Xue; Jie Yan; Yuxia Xu; Jiangning Zhou; Guanghui Wang
Journal:  J Biol Chem       Date:  2010-10-04       Impact factor: 5.157

2.  No association between NRG1 and ErbB4 genes and psychopathological symptoms of schizophrenia.

Authors:  Sarah Tosato; Martina Zanoni; Chiara Bonetto; Federica Tozzi; Clyde Francks; Elisa Ira; Simona Tomassi; Mariaelena Bertani; Dan Rujescu; Ina Giegling; David St Clair; Michele Tansella; Mirella Ruggeri; Pierandrea Muglia
Journal:  Neuromolecular Med       Date:  2014-08-21       Impact factor: 3.843

Review 3.  Viral infection, inflammation and schizophrenia.

Authors:  Rachel E Kneeland; S Hossein Fatemi
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-02-10       Impact factor: 5.067

4.  Dysbindin-1 mutant mice implicate reduced fast-phasic inhibition as a final common disease mechanism in schizophrenia.

Authors:  Gregory C Carlson; Konrad Talbot; Tobias B Halene; Michael J Gandal; Hala A Kazi; Laura Schlosser; Quan H Phung; Raquel E Gur; Steven E Arnold; Steven J Siegel
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-03       Impact factor: 11.205

5.  General and domain-specific neurocognitive impairments in deficit and non-deficit schizophrenia.

Authors:  János M Réthelyi; Pál Czobor; Patrícia Polgár; Beatrix Mersich; Sára Bálint; Eva Jekkel; Krisztina Magyar; Agnes Mészáros; Agnes Fábián; István Bitter
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-07-27       Impact factor: 5.270

Review 6.  Molecular genetics of the psychosis phenotype.

Authors:  Pamela DeRosse; Anil K Malhotra; Todd Lencz
Journal:  Can J Psychiatry       Date:  2012-07       Impact factor: 4.356

Review 7.  Neuregulin-1 signalling and antipsychotic treatment: potential therapeutic targets in a schizophrenia candidate signalling pathway.

Authors:  Chao Deng; Bo Pan; Martin Engel; Xu-Feng Huang
Journal:  Psychopharmacology (Berl)       Date:  2013-02-07       Impact factor: 4.530

8.  A systematic meta-analysis of the association of Neuregulin 1 (NRG1), D-amino acid oxidase (DAO), and DAO activator (DAOA)/G72 polymorphisms with schizophrenia.

Authors:  Vinita Jagannath; Miriam Gerstenberg; Christoph U Correll; Susanne Walitza; Edna Grünblatt
Journal:  J Neural Transm (Vienna)       Date:  2017-09-01       Impact factor: 3.575

9.  Brain RGS4 and RGS10 protein expression in schizophrenia and depression. Effect of drug treatment.

Authors:  G Rivero; A M Gabilondo; J A García-Sevilla; L F Callado; R La Harpe; B Morentin; J J Meana
Journal:  Psychopharmacology (Berl)       Date:  2012-10-24       Impact factor: 4.530

Review 10.  Losing your inhibition: linking cortical GABAergic interneurons to schizophrenia.

Authors:  Melis Inan; Timothy J Petros; Stewart A Anderson
Journal:  Neurobiol Dis       Date:  2012-11-29       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.